Getronics Resets Business with Global Rebrand
Today, Getronics announces a global rebrand marking the culmination of months of work following its acquisition in July 2020.
The rebrand will make Getronics stand out in a crowded market, where it is already a leader in managed workplace services (*Gartner Magic Quadrant February 2020).
Getronics delivers end-to-end capabilities designed to build digital experiences that drive exceptional business outcomes. Getronics has over 2000 customers, including Credit Agricole, Intersnack, and Inditex, as well as Ford Motors, which the company has served for over 35 years.
“Our company is on a mission to harness technology to transform our clients’ businesses. Our rebrand gives us the opportunity to re-energise our entire organisation. We have not needed to buy anything or create anything new from scratch to do this, it was all there within our business,” says Kenton Fine, Executive Chairman. “Now we have brought it all together, with a new brand and clarity to our offering. It is hugely exciting for us, our talented teams, and our fantastic customers. We know this will give us the fuel to propel our organic growth and to ensure that our customers thrive.”
The rebrand, led by Getronics senior leadership team – CTO, Harsha Gowda, COO and Head of Global Delivery, Rogier Bronsgeest, Group Transformation Director, Andre Ribbens, Getronics CFO, Mike Field, and recently appointed CCO, Tom Regent – will enable the Getronics team, customers, and partners together to harness the power of technology and to revolutionise the digital experience, thereby transforming businesses and advancing communities.
“We have reimagined what our digital future might look like, not just for the team at Getronics, but for all of our clients. Our previous identity did not stand out in the way we wanted. Because of our journey of expansion, we had some legacy brands which were not distinct and did not clarify our offering. Our new identity, of which all of our 4000 colleagues have had a sneak preview, makes Getronics distinctive,” concludes Getronics CTO, Harsah Gowda.
Getronics offers the following integrated services: Digital Workplace, Cloud Services, Smart Spaces, Business Applications, Security & Compliance, Field & On-Site Support, Service Desk, and Network Services. Getronics now has a striking visual identity, distinguishing it in the marketplace, establishing the group’s role in reimagining a digital future for business.
-ENDS-
Executive services
Getronics has defined its offering under 8 services:
● Digital Workplace – an always-on, intuitive experience
● Cloud Services – public, private and on-premises
● Smart Spaces – transforming work spaces into smart spaces
● Business Applications – applications that build trust and loyalty
● Security & Compliance – delivering trust and peace of mind
● Field & On-Site Support - any device, any time, anywhere
● Service Desk – get reassurance and peace of mind
● Network Services - connecting people and applications
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005507/en/
Contact information
Media enquiries:
Nadia Gabbie
nadia.gabbie@getronics.com
+44 7973 177323
Stephanie Kronson
stephanie.kronson@getronics.com
+447931577367
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom